These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27690553)

  • 1. Ultra-Low-Dose Buprenorphine for Mental Pain: Response to Ruan et al.
    Yovell Y; Bar G
    Am J Psychiatry; 2016 Oct; 173(10):1043-1044. PubMed ID: 27690553
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
    La Vincente SF; White JM; Somogyi AA; Bochner F; Chapleo CB
    Clin Pharmacol Ther; 2008 Jan; 83(1):144-52. PubMed ID: 17568402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.
    Hay JL; La Vincente SF; Somogyi AA; Chapleo CB; White JM
    Eur J Pain; 2011 Mar; 15(3):293-8. PubMed ID: 20728384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient.
    Book SW; Myrick H; Malcolm R; Strain EC
    Am J Psychiatry; 2007 Jun; 164(6):979. PubMed ID: 17541066
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
    Kögel B; Christoph T; Strassburger W; Friderichs E
    Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
    van Niel JC; Schneider J; Tzschentke TM
    Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid-induced respiratory effects: new data on buprenorphine.
    Dahan A
    Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Co-Administering Full µ-Opioid Receptor Agonists with Buprenorphine and Mixed Opioid Agonists.
    Ruan X; Luo J; Kaye AD
    Drug Res (Stuttg); 2017 Mar; 67(3):189-190. PubMed ID: 27926949
    [No Abstract]   [Full Text] [Related]  

  • 9. Buprenorphine maintenance therapy hinders acute pain management in trauma.
    Harrington CJ; Zaydfudim V
    Am Surg; 2010 Apr; 76(4):397-9. PubMed ID: 20420250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine in combination with naloxone at a ratio of 15:1 does not enhance antinociception from buprenorphine in healthy cats.
    Slingsby LS; Murrell JC; Taylor PM
    Vet J; 2012 Jun; 192(3):523-4. PubMed ID: 22030474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Letter From Ruan and Bumgarner: Breakthrough Pain Associated With a Reduction in Serum Buprenorphine Concentration During Dialysis.
    Salili AR; Müller D; Skendaj R; Jehle AW; Taegtmeyer AB
    Clin Ther; 2016 Mar; 38(3):679-80. PubMed ID: 26811185
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone.
    Ling W; Hillhouse M; Jenkins J; Miotto K; Torrington M; Chapleo C
    J Addict Med; 2012 Jun; 6(2):118-23. PubMed ID: 22475985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug buprenorphine can treat patients addicted to heroin or prescription pain medications.
    Clark HW
    W V Med J; 2003; 99(1):42. PubMed ID: 12762216
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.
    McCormick Z; Chu SK; Chang-Chien GC; Joseph P
    Pain Med; 2013 Aug; 14(8):1187-91. PubMed ID: 23647815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversibility of opioid receptor occupancy of buprenorphine in vivo.
    Englberger W; Kögel B; Friderichs E; Strassburger W; Germann T
    Eur J Pharmacol; 2006 Mar; 534(1-3):95-102. PubMed ID: 16490191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine: new pharmacological aspects.
    Cowan A
    Int J Clin Pract Suppl; 2003 Feb; (133):3-8; discussion 23-4. PubMed ID: 12665117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine produces naltrexone reversible alterations of immune status.
    Carrigan KA; Saurer TB; Ijames SG; Lysle DT
    Int Immunopharmacol; 2004 Mar; 4(3):419-28. PubMed ID: 15037219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.